New Stock News | Zhii Biotech filed an application to the Hong Kong Stock Exchange. Its core product SK08 and key product SK10 have achieved multiple research and development milestones.

According to the disclosure by the Hong Kong Stock Exchange on June 18, Guangzhou Zhiyi Biotechnology Co., Ltd. (referred to as: Zhiyi Biotech) submitted an application to the Hong Kong Stock Exchange Main Board, with Guotou Securities International and CISI FIN as its joint sponsors. Company Profile The prospectus shows that Zhiyi Biotech is a clinical-stage biopharmaceutical company, focusing on the area of Live Biotherapeutics Products (LBP), with business covering gastrointestinal diseases, tumors, tumor-related complications, metabolic diseases, and autoimmune diseases. As of the last practicable date, the company owns a core product SK08, which is a candidate LBP drug used in the treatment of irritable bowel syndrome with diarrhea (IBS-D), acute childhood diarrhea caused by rotavirus (rotavirus diarrhea in children), ulcerative colitis (UC), as well as in combination with anti-PD-1/L1 monoclonal antibodies for the treatment of advanced solid tumors; a key product SK10, which is an inactivated LBP candidate drug used for the prevention and treatment of chemotherapy-induced diarrhea (CID); and four pipeline preclinical candidate drugs. The company's core product SK08 and key product SK10 have achieved multiple research and development milestones. According to Frost & Sullivan data, the company's core product SK08 is the first LBP to receive registration clinical trial approval from the National Medical Products Administration and the US FDA, and is also the world's first LBP to enter clinical development using fragile bacterium. As of the last practicable date, it is the only biotherapeutic drug in late-stage clinical development in the IBS-D field globally. If approved, SK08 is expected to be the first marketed product for this indication. The company's key product SK10 is an orally administered, internally developed, inactivated LBP based on a new strain of fragile bacterium, used for the prevention and treatment of CID. According to Frost & Sullivan data, SK10 is the first candidate LBP based on fragile bacterium to receive FDA approval for clinical development, and is also the world's first candidate LBP for CID. Additionally, as of the last practicable date, SK10 is the only candidate LBP in the world in clinical development for the prevention of CID. Financial Information Income In the fiscal years 2024 and 2025, the company recorded income of RMB 721,000 and RMB 2.407 million respectively. Gross Profit In the fiscal years 2024 and 2025, the company's gross profit was RMB 298,000 and RMB 231,000 respectively. Net Loss and Comprehensive Income for the Year In the fiscal years 2024 and 2025, the company recorded a net loss of RMB 63.998 million and RMB 69.393 million... (please let me know if you need me to continue)